The Journal of clinical endocrinology and metabolism · 2007
Determination of the elimination half-life of fibroblast growth factor-23.
СтатьяResearch Support, N.I.H., IntramuralНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Khosravi Azarmindokht, Cutler Carolee M, Kelly Marilyn H, Chang Richard, Royal Richard E, Sherry Richard M, Wodajo Felasfa M, Fedarko Neal S, Collins Michael T
Аннотация
CONTEXT: Tumor-induced osteomalacia (TIO) is a rare paraneoplastic disease caused by mesenchymal tumors that secrete fibroblast growth factor-23 (FGF-23), a newly-described vitamin D and phosphate-regulating hormone. Surgical removal of the tumor, the ectopic source of circulating FGF-23, offers the opportunity to determine the elimination half-life of FGF-23.
OBJECTIVE: The aim of the study was to determine the elimination half-life of FGF-23.
PATIENTS/METHODS: The tumors were removed from three patients with TIO, and serum samples were taken every 30 min for up to 72 h after the operation. FGF-23 was measured by both a C-terminal/intact assay and an intact assay, and the elimination half-life was determined by one phase exponential decay methodology.
SETTING: The Mark O. Hatfield Clinical Research Center of the National Institutes of Health, a tertiary referral clinical research center, was the setting for the study.
RESULTS: The elimination life of FGF-23 as determined by C-terminal/intact and intact assays was 46 +/- 12 and 58 +/- 34 min, respectively.
CONCLUSIONS: The plasma half-life of serum FGF-23 is in the range of 46-58 min.
OBJECTIVE: The aim of the study was to determine the elimination half-life of FGF-23.
PATIENTS/METHODS: The tumors were removed from three patients with TIO, and serum samples were taken every 30 min for up to 72 h after the operation. FGF-23 was measured by both a C-terminal/intact assay and an intact assay, and the elimination half-life was determined by one phase exponential decay methodology.
SETTING: The Mark O. Hatfield Clinical Research Center of the National Institutes of Health, a tertiary referral clinical research center, was the setting for the study.
RESULTS: The elimination life of FGF-23 as determined by C-terminal/intact and intact assays was 46 +/- 12 and 58 +/- 34 min, respectively.
CONCLUSIONS: The plasma half-life of serum FGF-23 is in the range of 46-58 min.